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Abstract
Chronic immune activation is a harbinger of AIDS-associated non-Hodgkin lymphoma (AIDS-
NHL), yet the underlying basis is unclear. Microbial translocation, the passage of microbial 
components from the gastrointestinal tract into the systemic circulation, is a source of systemic 
immune activation in HIV infection and may be an important contributor to the chronic B cell 
activation and subsequent AIDS-NHL development. We measured biomarkers of microbial 
translocation including bacterial receptors/antibodies, intestinal barrier proteins, and macrophage 
activation-associated cytokines/chemokines, in serum from 200 HIV-infected men from the 
Multicenter AIDS Cohort Study prior to their AIDS-NHL diagnosis (mean=3.9 years; SD=1.6 
years) and 200 controls. Controls were HIV-infected men who did not develop AIDS-NHL, 
individually matched to cases on CD4+ T cell count, prior antiretroviral drug use, and recruitment 
year into the cohort. Biomarkers of bacterial translocation and intestinal permeability were 
significantly increased prior to AIDS-NHL. Lipopolysaccharide-binding protein (LPB), fatty acid 
binding protein 2 (FABP2) and soluble CD14 had 1.6-, 2.9-, and 3.7-fold increases in risk for each 
unit increase on the natural log scale, respectively. Haptoglobin had a 2.1-fold increase and 
endotoxin-core antibody a 2.0-fold decrease risk for AIDS-NHL (4th versus 1st quartile). 
Biomarkers of macrophage activation were significantly increased prior to AIDS-NHL: B-cell 
activation factor (BAFF), IL18, monocyote chemoatractant protein-1 (MCP1), Tumor Necrosis 
factor-α (TNFα), and CCL17 had 2.2-, 2.0-, 1.6-, 2.8-, and 1.7-fold increases in risk for each unit 
increase on the natural log scale, respectively. These data provide evidence for microbial 
translocation as a cause of the systemic immune activation in chronic HIV infection preceding 
AIDS-NHL development.
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Introduction
Non-Hodgkin lymphoma (NHL) is an important cause of morbidity and mortality in people 
with HIV infection.[1–3] While the incidence of AIDS-associated NHL (AIDS-NHL) has 
decreased with combination antiretroviral therapy (cART), it still results in 23–30% of 
AIDS-related deaths in countries with readily accessible cART.[4–7] There are several AIDS-
NHL subtypes; all are of B cell origin, yet subtypes are thought to differ in their 
pathogenesis.[8–10] Primary central nervous system lymphomas (PCNSLs) are less common, 
but more aggressive, than Burkkit’s lymphoma (BL), diffuse large B cell lymphoma 
(DLBCL), or other systemic tumors.[11] Two major mechanisms are believed to contribute to 
the genesis of AIDS-NHL: i) the loss of immunoregulatory control of Epstein Barr virus 
(EBV) infected B cells, resulting from impaired T cell function; and ii) chronic B cell 
activation, which leads to DNA modifying events (oncogene mutations and translocations) 
that contribute to lymphomagenesis.[12–14]
Epidemiologic evidence suggests a role for B cell stimulatory cytokines and molecules in 
the development of AIDS-NHL. Elevated levels of circulating cytokines (IL6, IL10, 
CXCL13, Tumor Necrosis factor-α [TNFα], Interferon-γ inducible protein [IP-10]/
CXCL10), soluble receptors (sCD23, sCD27, sCD30), and markers of inflammation and 
immune activation (neopterin, κ and λ immunoglobulin free light chains) have been shown 
to precede the development of AIDS-NHL by up to 7 years.[11, 15] Examining potential 
sources of chronic B cell activation in the setting of HIV infection may provide insights into 
the etiology of AIDS-NHL. Microbial components (e.g., lipopolysaccharide [LPS]) passing 
across the intestinal epithelial barrier into peripheral circulation (termed microbial 
translocation) has been shown to contribute to systemic immune activation in chronic HIV 
infection, and may be a contributor to the chronic B cell activation that predisposes to AIDS-
NHL.[16, 17] Microbial translocation and the consequential systemic immune activation is 
influenced by the loss of integrity and structural damage to the gastrointestinal barrier in 
chronic HIV infection, which can be measured by circulating barrier proteins including fatty 
acid binding protein (FABP) 2 and haptoglobin.[18][17] The presence of LPS in the 
bloodstream leads to consumption of antibodies against LPS (anti-endotoxin-core protein 
IgM, otherwise known as EndoCAb), increased production of LPS binding protein (LBP) 
and receptor (sCD14), and increase in activation of macrophages and the secretion of nerous 
cytokines and chemokines.
In this study, we sought to determine the association between these biomarkers of microbial 
translocation, intestinal integrity, and macrophage activation and subsequent AIDS-NHL 
development, to support our hypothesis that microbial translocation contributes to chronic B 
cell activation and AIDS-NHL risk. We also examined several B cell activation markers to 
confirm prior reports of significant elevations preceeding AIDS-NHL diagnosis.
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Methods
Study population
This is a nested case-control study utilizing serum specimens from participants in the 
Multicenter AIDS Cohort Study (MACS), a prospective cohort study of the natural and 
treated history of HIV/AIDS in men who report sex with men. [19, 20] The participants were 
recruited from four U.S. metropolitan areas (Baltimore/Washington, Chicago, Los Angeles, 
and Pittsburgh), and study visits have been held at 6-month intervals beginning in 1983 
(www.statepi.jhsph.edu/macs/macs.html). A total of 7,350 men have been enrolled in the 
MACS.
Participants were selected for study on the basis of pathologically confirmed AIDS-NHL 
after enrollment into the MACS and archival serum specimens available prior to cancer 
diagnosis (n=200). For each case, one control was selected randomly from all possible HIV-
infected MACS participants who had not developed AIDS-NHL as of November 2014, 
matched on: (i) CD4+ T cell counts (± 200/ul); (ii) prior antiretroviral drug use (ever versus 
never); and (iii) recruitment year into the cohort (1984–85, 1987–91, or 2001+). 
Additionally, cases treated with a potent combination of antiretroviral drugs were matched to 
controls on time since first therapy, and cases who became HIV-infected after recruitment 
into the cohort were matched to controls by their seroconversion date.
Biomarker determination
Serum levels of haptoglobin and anti endotoxin-core protein IgM were determined by 
ELISA according to the manufacturer’s directions (R&D Systems and Hycult Biotech, 
respectively). Serum levels of all other biomarkers were determined using the Luminex 
platform with custom-made panels produced by R&D systems. Briefly, Luminex 
microparticles pre-coated with analyte-specific antibodies were incubated with diluted 
serum samples, followed by a biotin–antibody and by a streptavidin–phycoerythin 
conjugate. The fluorescence intensity of each analyte’s microparticles was quantified using a 
Bioplex 200 (Luminex) System Analyzer (Bio-Rad), and the data analyzed using BioPlex 
Manager (v 4.1.1) software. The lower limit of detection (LLD) for each biomarker was set 
either as the lowest value that the BioPlex Manager software could calculate using the 
standard curve, or as the lowest value of the standard curve, whichever was smaller. For 
quality control, case and control samples were equally distributed across reaction plates, and 
replicates were included across the reaction plates to calculate coefficients of variation 
(CVs). All labotaroty personnel were blinded to the case-control status of samples. 
Additional assay details including LLD, dilution factors, detectable fractions, and CVs, are 
presented in Supplemental Table 1.
Statistical analysis
We analyzed our biomarkers as natural log-transformed continuous variables. Additionally, 
in exploratory analyses, we examined biomarker categories by quartiles according to the 
distribution among the controls. We calculated odds ratios (ORs) and 95% confidence 
intervals (CIs) representing the risk of AIDS-NHL associated with one log-unit change in 
biomarker levels or risk of AIDS-NHL associated with each of the 2nd, 3rd, and 4th 
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quartiles compared to the 1st quartile, using conditional logistic regression. In addition to the 
matching factors, ORs were adjusted for covariates selected a priori for their association 
with AIDS-NHL in prior studies including age (continuous), race/ethnicity (categorical), and 
Hepatatis C virus (HCV) infection status. Each biomarker was tested for association with 
AIDS-NHL in separate regression models. Additionally, we tested for trends across quartiles 
using a continuous variable with values representing the medians of each category. We 
examined patterns of AIDS-NHL risk associated with biomarkers according to subgroups of 
systemic lymphomas or PCNSL. We also examined patterns of AIDS-NHL risk associated 
with biomarkers according to the time interval between serum sample collection and AIDS-
NHL diagnosis. We classified this lag time into two categories: < 4 years or ≥ 4 years. These 
categories were selected according to the natural distribution of lag times and wanting to 
ensure approximately equal number of participants in each category. In addition to these 
stratified analyses, we also tested for statistical interactions between biomarkers and lagtime 
using interaction terms in the models. Lastly, we calculated pairwise correlations between all 
biomarkers using Pearson’s correlation coefficient.
Results
Study population description
Cases and controls were similar in their distributions by recruitment year, CD4+ T cell 
count, and antiretroviral drug therapy, as expected based on the matched design (Table 1). 
The majority of controls and cases were non-Hispanic white (80.0% and 81.0% 
respectively). Cases tended to be older than controls, with 44.5% of cases ≥40 years, 
compared to 38.0% of controls. Cases were more likely to have acute or chronic HCV 
infection compared to controls (10.2% versus 6.5%). Both groups had relatively high levels 
of CD4+ T cells, with 51.5% of controls and 46.5% of cases having >400 CD4+ T cells/
mm3, and the majority were antiretroviral drug naïve (94.0% of controls and 94.5% of 
cases). The mean time from serum date to NHL diagnosis was 3.9 years; standard deviation 
of 1.6 years and a range of 1 month to 12 years. The majority of cases (69.5%) were 
systemic lymphomas, and DLBCL was the major subtype (48.2%).
Microbial translocation biomarkers
Levels of sCD14, FABP2, and LBP were associated with AIDS-NHL risk, with 3.71-, 1.64-, 
and 2.97-fold increases in risk for each unit increase on the natural log scale, respectively 
(Table 2, Figure 1). Additionally, participants with marker levels in the highest versus lowest 
quartile for haptoglobin, and EndoCAb, were at 2.18-fold increased, and 2-fold decreased, 
risk of AIDS NHL, respectively. For some markers (haptoglobin, FABP2, and LBP), there 
appeared to be a threshold effect for the highest quartile: an increased AIDS-NHL risk was 
only observed for participants with marker levels in the highest versus lowest quartiles. In 
comparison, for sCD14, AIDS-NHL risk was elevated similarly across the 2nd, 3rd, and 4th 
quartiles. Also, AIDS-NHL risk was reduced similarly across the 2nd, 3rd, and 4th quartiles 
for EndoCAb.
In subgroup analyses by lag time between pre-diagnostic serum collection date and AIDS-
NHL diagnosis date, EndoCAb, FABP2, and Haptoglobin demonstrated consistent 
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associations with AIDS-NHL risk across lag times, while other markers were more strongly 
associated with AIDS-NHL risk when measured close to diagnosis date (< 4 years, sCD14 
and LBP, Table 2). There was an association between increased AIDS-NHL risk and higher 
levels of FABP2, haptoglobin, and LBP, particularly among those men with systemic 
lymphoma in comparison to those with PCNSL (Figure 1, Supplemental Table 2). 
Conversely, higher levels of sCD14 were more strongly associated with PCNSL versus 
systemic lymphoma. EndoCAb appeared to be similarly associated with decreased risk of 
systemic lymphoma and PCNSL.
Macrophage-associated cytokines and chemokines
BAFF, CCL17, ICAM, IL18, and MCP1 were associated with AIDS-NHL, with 2.21-, 1.68-, 
1.66-, 1.93-, and 1.60-fold increases in risk for each unit increase on the natural log scale, 
respectively (Table 3, Figure 1). When modeled as quartiles, these biomarkers generally 
displayed dose-response relationships with AIDS-NHL risk (the higher the levels, the higher 
the risk). For sCD163, participants with levels in the highest versus lowest quartile were at 
1.94-fold increased AIDS-NHL risk. CCL17 and MCP1 displayed similar associations with 
AIDS-NHL risk when measured < 4 years or ≥ 4 years prior to diagnosis date (Table 3). 
BAFF and IL18, were more strongly associated with AIDS-NHL risk when measured close 
to diagnosis date (< 4 years), while ICAM and sCD163 displayed stronger associations 
when measured ≥ 4 years prior to diagnosis. BAFF and IL18 also displayed stronger 
associations with systemic lymphoma than PCNSL, while CCL17, ICAM, MCP1 
(Supplemental Table 2) were similarly associated with systemic and PCNSL risks. TRAIL 
was unassociated with AIDS-NHL overall, however we observed a statistically significant 
interaction (p=0.04) between TRAIL and lag time: higher TRAIL levels were associated 
with AIDS-NHL risk only when measured ≥ 4 years prior to AIDS-NHL diagnosis.
B cell activation markers
There was a significant association between B cell activation markers with AIDS-NHL risk, 
with ORs ranging from 1.23 to 4.91 for each unit increase on the natural log scale 
(Supplemental Table 3, Figure 1). These associations were observed when markers were 
measured close to diagnosis (< 4 years), and persisted when markers were measured ≥ 4 
years prior to diagnosis. These biomarkers were significantly associated with both systemic 
lymphoma and PCNSL, although CXCL13 appeared to be more strongly associated with 
systemic lymphoma while sCD23 was more strongly associated with PCNSL (Supplemental 
Table 2, Figure 1).
We observed strong correlations between several markers of microbial translocation 
(sCD14), macrophage activation (sCD163, ICAM, BAFF, and IL18), and B cell activation 
(IP10 and sCD27), with Pearson’s pairwise correlations ranging from 0.3 to 0.6.
Discussion
In this prospective study, we defined the association between serum levels of molecules 
associated with microbial translocation and immune activation/inflammation with 
subsequent AIDS-NHL diagnosis. Key novel observations were that markers of bacterial 
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exposure and host response to bacteria (sCD14, LBP, EndoCAb), intestinal barrier 
dysfunction (FABP2 and Haptoglobin), and macrophage activation (BAFF, CCL17, ICAM, 
IL18, MCP1, and sCD163,) were highly predictive of subsequent AIDS-NHL diagnosis in 
men with HIV infection. Importantly, these associations were observed after careful 
adjustment of HIV disease status, immune suppression, and antiretroviral drug therapy.
sCD14 displayed the strongest association with AIDS-NHL of all the microbial translocation 
markers examined. sCD14 is the soluble form of the LPS co-receptor and is produced by 
macrophages on exposure to LPS and other inflammatory activators.[21, 22] Furthermore, 
sCD14 was more strongly associated with AIDS-NHL when measured close to the diagnosis 
date (< 4 years), and was more strongly associated with PCNSL than systemic lymphoma. 
PCNSL is an aggressive presentation of AIDS-NHL believed to arise principally due to the 
oncogenic properties of uncontrolled EBV reactivation in severely immunocompromised 
individuals. These observations are consistent with the hypothesis that microbial 
translocation is a consequence of compromised gut immunity (lower CD4+ T cell count), 
which occurs close to the time of AIDS-NHL diagnosis,[23] and is more strongly associated 
with PCNSL in comparison to systemic lymphoma development.[24] In a prior study, serum 
levels of sCD14 greater than or equal to 1.76 ×106 pg/ml (median value in controls) were 
associated with a 2.7-fold increased risk of AIDS-NHL, in samples collected a median of 1 
year prior to AIDS-NHL diagnosis.[25] Our results build on this prior observation in a larger 
study sample with a longer lag time from specimen collection to AIDS-NHL diagnosis.
LBP was another biomarker found to be strongly associated with subsequent AIDS-NHL 
diagnosis, particularly when it was measured close to NHL diagnosis date (< 4 years); 
however, in contrast to sCD14, LBP was more strongly associated with systemic lymphoma 
when compared to PCNSL. LBP is an LPS binding protein which promotes binding of LPS 
to its receptor. Additionally, we observed that levels of EndoCAb, a neutralizing antibody 
against LPS, were significantly reduced prior to AIDS-NHL, with consistent associations 
across lag times from blood collection to AIDS-NHL diagnosis, and between systemic 
lymphoma and PCNSL. In prior studies, LBP and EndoCAb have been described as indirect 
markers of LPS: LBP is positively assocaited while EndoCAb is inversely associated with 
LPS levels [16]. Prior research suggests that HIV-infection impairs EndoCAb response.[26] 
Thus, the observed inverse association between EndoCAb levels and AIDS-NHL risk is 
consistent with the notion that LPS in circulation among HIV-infected persons at risk for 
NHL depletes circulating EndoCAb, further supporting the hypothesized role of microbial 
translocation in AIDS-NHL.
Structural damage to the gastrointestinal tract in chronic HIV infection has been well-
described,[18] and the integrity of the intestinal barrier is an important factor in HIV-related 
systemic immune activation that may also influence lymphomagenesis.[17] FABP2 (a lipid 
transport protein and marker of enterocyte damage) and haptoglobin (a physiological 
modulator of intercellular tight junctions) are markers of intestinal barrier integrity. For both 
of these markers, a significantly increased risk for AIDS-NHL risk was observed only 
among those men with the highest levels (4th quartile), particularly for systemic lymphoma. 
In prior studies, higher levels of FABP2 were seen to be associated with lower CD4+ T cell 
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counts, liver disease progression, and mortality in HIV infection.[27–29] To our knowledge, 
no prior studies have examined serum haptoglobin in HIV infection or lymphoma.
We previously showed that pre-NHL diagnosis serum levels of markers related to B-cell 
activation (sCD23, sCD27, CXCL13, IL6, IL10, IP10, and TNFα) were associated with risk 
for AIDS-NHL.[11, 13, 15, 30] In this study, we found that other cytokines and chemokines 
that are mainly secreted by activated macrophages (BAFF, CCL17, ICAM, IL18, MCP1, and 
sCD163) were associated with risk for AIDS-NHL.[31–35] Macrophages have numerous 
functions related to inflammation, immunity, and tumor growth, and can be phenotypically 
polarized by the microenvironment to become M1 or M2. M1 typically secrete pro-
inflammatory cytokines (TNFα, IL-6), while M2 mainly promote Th2 responses, 
immunosuppression, and tumor promotion.[31, 36] It is interesting to note that many of the 
cytokines or chemokines associated with AIDS-NHL risk are typically produced by M1 
polarized macrophages, including IP10, TNFα, IL18, IL6 and BAFF, [31, 32, 36] which may 
be reflecting microbial translocation and activation of macrophages by LPS. Some notable 
M2 markers, including CCL17 and CD163, [31, 36] were also associated with AIDS-NHL 
risk, possibly reflecting the presence of tumor-associated, tumor growth-promoting, 
macrophages. However additional studies are needed to elucidate these associations.
Interestingly, we found an association between pre-diagnosis serum levels of CCL17 
(TARC) and the risk for AIDS-NHL. CCL17 was previously shown to be associated with the 
development of Hodgkin lymphoma (HL), suggesting that there may be common 
mechanisms contributing to the development of these lymphatic system cancers as they 
relate to CCL17.[37] High levels of sCD163 (4th quartile) were associated with increased 
AIDS-NHL risk, particularly PCNSL (which tend to be EBV-assocaited). In prior work, 
sCD163 correlated with plasma EBV-DNA in patients with HL [38]. Thus, we hypothesize 
that CCL17 and sCD163 may be associated with EBV reactivation in AIDS-NHL and HL.
We also found that pre-diagnosis levels of BAFF were associated with risk for AIDS-NHL. 
BAFF is a member of the TNF family of cytokines and plays an important role in normal B 
cell proliferation and activation. High levels of soluble BAFF may be contributing to 
prolonged B cell survival and increased susceptibility to mutation and transformation.[39] 
Prior studies have found that BAFF was elevated in patients with NHL and correlated with 
aggressive disease.[40]
The question of whether microbial translocation and macrophage activation markers are 
etiologically associated with AIDS-NHL development is impossible to determine in the 
context of an observational study. Interestingly, sCD14 was highly correlated with B cell 
activation markers (sCD27 and IP10), providing a link between microbial translocation and 
the B cell activation that precedes AIDS-NHL. However, pre-clinical disease in the cases 
may be responsible for the observed associations. Interestingly, we found that risk estimates 
for many of our markers were comparable when analyses were stratified by short (< 4 years) 
or long (≥ years) lag time from specimen collection to AIDS-NHL diagnosis, suggesting that 
the associations are less likely to be due to undiagnosed disease. Some notable exceptions 
were sCD14 and LBP, both of which were more strongly associated with AIDS-NHL when 
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measured closer to NHL diagnosis, suggesting a role of undiagnosed AIDS-NHL in the 
observed associations.
Systemic immune activation occurs early in the course of HIV infection.[16, 17] Therefore, it 
is reasonable to speculate that a failure to control immune activation may contribute to 
lymphomagenesis. In accordance with this, a recent study showed that plasma levels of LBP, 
FABP2 and IL6 were significantly elevated in patients from whom antiretroviral drug 
treatment was introduced during chronic HIV infection. In contrast, patients who started 
treatment with a potent combination of antiretroviral drugs at the time of HIV diagnosis 
were able to normalize their levels of LBP, FABP2 and IL6.[41] This finding supports early 
introduction of therapy to limit systemic immune activation and thereby reduce the 
incidence of lymphomagenesis. Even though this is an interesting hypothesis, we were not 
able to test it in this study, as only a small percentage of cases and controls (6%) were 
treated with potent combinations of antiretroviral drugs.
The main strength of this study is the inclusion of a large sample of known AIDS-NHL 
cases with detailed longitudinal covariate data and specimen availability before AIDS-NHL. 
Compared to prior studies, we examined a larger number of biomarkers indicative of 
microbial translocation and related immune activation, with longer lag times from biomarker 
measurement to AIDS-NHL diagnosis. Also, our larger study population allowed us to 
examine differences in biomarker associations by lag time and site (CNS versus systemic). 
In addition to the markers presented in this paper, this study population has been 
characterized with respect to a number of important biomarkers related to AIDS-NHL, 
permitting us to evaluate our findings in this context. Although we controlled for CD4+ T-
cell numbers and date of HIV infection among seroconverters, our observed associations 
may still be influenced by residual confounding by HIV progression. Also, our population 
consisted largely of white men who have sex with men, who developed lymphoma prior to 
initiation of HAART, potentially limiting the generalizability of the findings. We did not 
correct for type 1 error, thus we cannot exclude the possibility of chance findings. However, 
our goal of this study was to examine several biomarkers in a related pathway to 
demonstrate strength of evidence (not necessarily statistical significance for a single 
biomarker) for a role of microbial translocation in AIDS-NHL, thus type 1 error correction 
may not be appropriate.
Here we show that systemic immune activation in chronic HIV infection plays a prominent 
role in the development of AIDS-NHL. Additionally, the cytokine profile seen to precede 
AIDS-NHL diagnosis is consistent with an M1 macrophage activation, which in part may 
driven by endotoxin exposure due to microbial translocation. Future research is needed to 
better understand their biologic basis. For example, studies are needed to better define how 
LPS drives chronic B-cell activation and subsequent AIDS-NHL development. If these 
results are replicated, attenuation of microbial translocation-induced immune activation 
could be an effective therapeutic strategy to reduce AIDS-NHL risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Overall AIDS-NHL, systemic lymphoma, and PCNSL risk associated with 1-unit increase in 
biomarkers on the natural log scale (OR=box, 95% CI=bar).
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Table 1
Select characteristics of AIDS-NHL cases and controls
HIV-infected controls (n = 200) AIDS-NHL cases (n = 200)
Count Percentage Count Percentage
Recruitment cohort
 1984–1985 169 84.5% 169 84.5%
 1987–1991 24 12.0% 24 12.0%
 2001+ 7 3.5% 7 3.5%
Race
 White, non-Hispanic 160 80.0% 162 81.0%
 Black, non-Hispanic 23 11.5% 17 8.5%
 Hispanic 16 8.0% 21 10.5%
 Asian or Pacific Islander 1 0.5% 0
Age*
 < 30 31 15.5% 28 14.0%
 30 – 39 93 46.5% 83 41.5%
 40 – 49 61 30.5% 70 35.0%
 ≥ 50 15 7.5% 19 9.5%
Body mass index (mean ± SD)* 23.7 ± 2.8 23.9 ± 3.1
HCV status*
 Negative 180 90.5% 171 86.8%
 Acute or chronic infection 13 6.5% 20 10.2%
 Cleared 6 3.0% 6 3.0%
 Unknown 1 3
CD4+ T-cells/mm3*
 < 200 40 20.0% 44 22.0%
 200 – 399 57 28.5% 63 31.5%
 ≥400 103 51.5% 93 46.5%
 Unknown
Prior HAART exposure*
 No 188 94.0% 189 94.5%
 Yes 12 6.0% 11 5.5%
Time from serum date to NHL diagnosis, years (mean ± SD) N/A 3.9 ± 1.6
NHL site
 Systemic 139 69.5%
 Central Nervous System 61 30.5%
NHL subtype (systemic only)
 Diffuse large B-cell lymphoma 67 48.2%
 Burkitt Lymphoma 23 16.5%
 Lymphoplasmacytic lymphoma 2 1.4%
 Peripheral T-cell lymphoma 2 1.4%
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HIV-infected controls (n = 200) AIDS-NHL cases (n = 200)
Count Percentage Count Percentage
 Primary effusion lymphoma 1 0.7%
 Follicular lymphoma 1 0.7%
 NHL, NOS 43 30.9%
Tumor EBV status
 Negative 28 31.8%
 Positive 60 68.2%
 Unknown 88
NHL, non-Hodgkin lymphoma; SD, standard deviation; HCV, hepatitis C virus; HAART, highly active antiretroviral therapy; EBV, Epstein-barr 
virus
*
The reference date for these variables is the blood collection date which was used for testing serum biomarkers
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